-
Use of novel cell
death inhibitors developed at BCRI to target drug kamagra delivery to
tumors and reduce toxicity to normal tissue.
-
New approaches to
protect normal cells during chemotherapy to limit drug
toxicity and/or increase drug dosages to more effective levels.
-
A method to
accurately monitor the effectiveness of chemotherapy
(based on identification of dying cells) during the initial days
of treatment that should lead to fewer failed therapie
-
Identification and
study of a new, non-toxic herbal treatment for hard-to-cure,
drug-resistant ovarian cancer
-
Study and
characterization of a modified drug for the treatment of
prostate and ovarian cancer
-
Development and
study of a new protocol for the treatment of patients with
relapsed leukemias
-
Detection of
new mechanisms involved in death of cancer cells in response
to treatment (activation of “serine-proteases”) that will lead
to design of completely new treatment strategies.
-
Development of a new in vitro assay
to study drug effects on wound healing that does not require use
of animals
-
Studies on the mechanism of action
of the normal tissue component hyaluronate that promotes wound
healing
-
Studies of mechanism of action and
clinical applicability of the new class of anti-tumor and
anti-viral drugs, cytotoxic ribonucleases (Onconase).
